Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option
October 29, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million...
Karyopharm Therapeutics Announces Management Change
October 26, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Mike Falvey, Executive Vice President,...
Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes
October 11, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal...
Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes
October 09, 2018 16:01 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market and...
U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review
October 05, 2018 17:43 ET
|
Karyopharm Therapeutics Inc.
-- Application Seeks Accelerated Approval for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma -- -- PDUFA Date Set for April 6, 2019 -- NEWTON, Mass., Oct. 05, 2018 ...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 01, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s...
Karyopharm to Participate in Upcoming Investor Conferences
September 25, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management team...
Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
September 20, 2018 16:05 ET
|
Karyopharm Therapeutics Inc.
-- Two Oral Presentations Highlighting Previously Reported Phase 2b STORM Data in Patients with Penta-Refractory Multiple Myeloma and Phase 2b SADAL Data in Patients with Relapsed or Refractory...
Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting
September 13, 2018 19:20 ET
|
Karyopharm Therapeutics Inc.
-- Oral Selinexor Achieves 26.2% Overall Response Rate and Duration of Response of 4.4 Months in Overall Study Population; Responses Typically Occurred Within 1 Cycle (4 Weeks) of Treatment -- ...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 04, 2018 16:05 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...